Sayed Matar

Postdoctoral research fellow @BWHPath
Former AP resident @AUBMC_Official

Applying for #PathMatch2024

[Toni Choueiri, MD @DrChoueiri]

Our @DanaFarber_GU and @LabSignoretti are looking for a junior pathologist/resident (at least 1 year of residency training) to join our group and lead one of our translational efforts in kidney cancer. Training in general pathology is ok as long as it is 6-12 months. Please contact us if you know someone who is interested and willing to spend at least 2 years in the lab. DM me or @LabSignoretti 😀

[Eddy Saad @eddy_saad]

Hello #MedTwitter!

I’m Eddy Saad, a @USJLiban graduate 🇱🇧 and currently a postdoc fellow studying kidney cancer and immunotherapy 🤓 @DanaFarber @harvardmed

Incredibly grateful for the opportunity to be applying for the #InternalMedicine #Match2025 !

AAMC ID: 16349429 #IMG

[Razan Mohanna @Rzn_Mh]

Hello #MedTwitter #MedX

I am Razan Mohanna, a @USJLiban 🇱🇧graduate and currently a research fellow at @BrighamWomens @harvardmed

Excited to be applying for #InternalMedicine #Match2025

Looking forward for this journey and to connect with fellow applicants and programs!

[Samer Salem, MD @SamerSalem18]

Hi #MedTwitter! I’m Samer Salem, an #IMG from Lebanon researching Kidney Cancer at @BrighamWomens and applying for Internal Medicine residency. So excited to pursue my dream specialty! #Match2025 #InternalMedicine

AAMC ID: 14538528

[Sayed Matar @SayedMatar12]

@rammal_rayan @UPMCPath @UPMCPathology @MSKPathology @KAD__MD Congratulations 🎊

[Toni Choueiri, MD @DrChoueiri]

PUBLICATION ALERT: Work on sarcomatoid RCC led by @TalalZarif1 (now @YaleIMed), @KarlSemaan/@marc_eid (@DanaFarber_GU) + super mentors #MattFreedman @SylvanBacaLab is now online in @CellReports

Wait for full tweetorial soon!

#teamwork @VanAllenLab @BraunMDPhD @LabSignoretti @srviswanathan et al.

Building on @ZiadBakouny (now @MSKCancerCenter + @VanAllenLab work: https://t.co/7adomGFPWF)

@OncoAlert

[Sayed Matar @SayedMatar12]

@yalepathology @Mansoura_un @YaleMed @YalePathRes I'm so excited to join your team.

[Yale Pathology @yalepathology]

Congratulations and welcome to our new #Pathology Resident Sayed Gamal Matar, MBBChB, of @Mansoura_un in Egypt. #MatchDay24 @YaleMed @YalePathRes

[Yale Internal Medicine @YaleIMed]

Congratulations to the newly matched residents in our Internal Medicine Traditional Residency Program! Welcome to @YaleMed @Yale @YNHH!

🧵 #MatchDay2024 #Residency #MedTwitter #Match2024

@MarkDSiegel1 @TradIMYale

[Sayed Matar @SayedMatar12]

@RanaaRadwan 🥰🥰🥰 ❤️❤️

[Yale Pathology @yalepathology]

Welcome to our new #Pathology residents! We are thrilled that you are joining us! #MatchDay24 @YaleMed @YalePathRes

[Sayed Matar @SayedMatar12]

@ijohn_62 @yalepathology @IHC_guy @YaleMed @YalePathRes @ijohn_62 🥰 I'm proud of you, too.

[Katrina Collins, MD || Pathologist @katcollmd]

🚨 #publicationalert #gupath
Together with @Andres_M_Acosta, we analyze paired conventional and sarcomatoid components of chRCC, aiming to clarify the genomic changes in sarcomatoid transformation
@liangchengmd @MichelleDunno17

Link to our article: https://t.co/x6kRxpgGvB

[Toni Choueiri, MD @DrChoueiri]

Pan-cancer epigenomic study: an innovative approach through 1 cc plasma/liquid biopsies! @sylvanbaca @DanaFarber #FreedmanLab @OncoAlert

#ESMO23 @myESMO with concomitant paper in @NatureMedicine

https://t.co/XyMFQXRI3x

[Katrina Collins, MD || Pathologist @katcollmd]

#slidearchiveseries biphasic hyalinizing psammomatous renal cell carcinoma
#gupath #pathtwitter #pathoutpic

🔬 biphasic pattern: smaller cells around basement membrane material within larger acini, forming a glomeruloid pattern
🧬 assoc with somatic mutations in NF2 gene

[Kidney Cancer @KidneyCancerBot]

#12Oct2023

🔥 Top News: #HighImpact paper release! 📰

New paper by Wilson, N et al. in International journal of cancer (https://t.co/3m7wYTlFzM)

Title: Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.

PMID: 3782318…

[Sayed Matar @SayedMatar12]

@fouad_boulos As you mentioned, stages are used for practicality. As humans, oncologists need to follow guidelines based on categorical variables for treatment decisions.
Maybe in the future, treatment will be guided by machine learning models that use continuous variables instead.

[Muhammad Ahsan Gill @ahsanuitis]

Orientation of a Whipple specimen on gross. Here's an article that explains it's grossing quick well.
https://t.co/cO07RP3efA
#GIpath #GrossPath

[Fouad Boulos @fouad_boulos]

Happy Thursday X-folks!

Yesterday's funky tumor is an invasive solid papillary carcinoma with mucin production. These tumors are some of the hardest to understand. Here's why.

They look like slightly irregular DCIS with fibrovascular cores, they are characteristically neuroendocrine, they can spindle, they often produce mucin, they are either invasive or noninvasive, they can have complete, attenuated, or lost myoepithelial cells even if noninvasive, invasion is determined by histology and it can either be IDC NST or invasive SPC with a solid pattern, they can metastasize while looking noninvasive, they are called solid but they can be cribriform, they are described as low grade but can be quite high grade. You get the gist.

The case from yesterday is eye-catching because it combines neuroendocrine/plasmacytoid cells, cells with cytoplasmic mucin, AND flattened cells around the tumor nests reminiscent of sustentacular cells in other neuroendocrine tumors, most notoriously paraganglioma, a finding I notice for the first time.

Voila. Hope you keep finding wonder in every little thing.

- Image 1 shows sustentacular-like cells with arrows pointing at them. Image 2 shows noninvasive solid papillary carcinoma from the same case.

@wusm_pathology @washupathedu #breastpath #breastcancer #PathTwitter #PathX #pathology